Antiangiogenic therapies targeting VEGF or VEGF receptors can have the effect of normalizing tumor blood vessels, removing a barrier to infiltration by immune cells, and reversing the immunosuppressive effects of VEGF signaling on dendritic cells and T lymphocytes. This evidence concerns the gene VEGFA and neoplasm.